Anti-Platelets in Chronic Obstructive Pulmonary Disease

2期已完成 NCT05567562

适应症	COPD, Emphysema, Emphysema or COPD
分期	2期
申办方	Brigham and Women's Hospital
状态	已完成
受试者人数	15 人
干预（药物）	dual anti-platelet therapy
开始日期	2024年3月27日
完成日期	2025年2月28日
结果公布日	2026年5月14日

摘要

This is a 6 week crossover study in current and former smokers with and without COPD to evaluate whether 2 weeks of dual antiplatelet therapy (aspirin 81mg and clopidogrel 75mg) improves pulmonary perfusion (i.e. blood flow in the lungs measured on a contrast CT scan) compared to placebo.

Pulmonary Microvascular Blood Volume, CV

After 2 weeks of therapy · CV

On Dual Anti-platelet Therapy	0.89 ± 0.079 CV
On Placebo	0.88 ± 0.072 CV
On Dual Anti-platelet Therapy, COPD	0.92 ± 0.064 CV
On Placebo, COPD	0.91 ± 0.052 CV
On Dual Anti-platelet Therapy, Controls	0.81 ± 0.051 CV
On Placebo, Controls	0.80 ± 0.042 CV

p-value	0.84

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and — University of Tennessee Graduate School of Medicine
Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster — Chiesi Farmaceutici S.p.A.
Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®T — Chiesi Farmaceutici S.p.A.
Tiotropium/Salmeterol Inhalation Powder in COPD — Boehringer Ingelheim
Risk Factors, Costs, and Impacts of ED Boarding — University of Maryland, Baltimore
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructiv — United Therapeutics

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский